ABSTRACT (1-piperidino)-1-piperidino] carbonyloxycamptothecin or Irinotecan] is a carbamate prodrug that is activated in vivo by carboxylesterase (CES)-2 to SN-38 (7-ethyl-10-hydroxycamptothecin), a potent topoisomerase I inhibitor. There is high interindividual variation when CPT-11 is used in the treatment of colorectal cancer. Several splice variants of CES2 are reported in the expressed sequence tag database. Real-time polymerase chain reaction was used to determine the abundance of the CES2 and splice variant of human carboxylesterase 2 (CES2⌬ 458 -473 ) transcripts in 10 paired samples of human tumor and normal colon tissue. The results showed that the CES2⌬ 458 -473 transcript accounts for an average of 6% of total CES2 transcripts in colon tissue, and there is large interindividual variation in CES2 expression in both tumor and normal colon samples. The carboxylesterase activity of the colon samples was determined by 4-methylumbelliferyl acetate hydrolysis assays and nondenaturing polyacrylamide gel electrophoresis followed by activity staining. Significant, positive correlations were found between CES2 expression levels and both measures of carboxylesterase activity. We cloned and expressed the CES2⌬ 458 -473 protein in Sf9 insect cells. The purification profiles and preliminary characterization of the CES2⌬ 458 -473 protein indicated that the expressed protein is folded and glycosylated like CES2. However, in vitro assays show that the CES2⌬ 458 -473 protein lacks 4-methylumbelliferyl acetate and irinotecan hydrolase activities. In conclusion, we found that the CES2⌬ 458 -473 protein is an inactive splice variant of CES2 and that its transcript is spliced at a relatively constant rate in tumor and normal colon tissue.
activity of the colon samples was determined by 4-methylumbelliferyl acetate hydrolysis assays and nondenaturing polyacrylamide gel electrophoresis followed by activity staining. Significant, positive correlations were found between CES2 expression levels and both measures of carboxylesterase activity. We cloned and expressed the CES2⌬ 458 -473 protein in Sf9 insect cells. The purification profiles and preliminary characterization of the CES2⌬ 458 -473 protein indicated that the expressed protein is folded and glycosylated like CES2. However, in vitro assays show that the CES2⌬ 458 -473 protein lacks 4-methylumbelliferyl acetate and irinotecan hydrolase activities. In conclusion, we found that the CES2⌬ 458 -473 protein is an inactive splice variant of CES2 and that its transcript is spliced at a relatively constant rate in tumor and normal colon tissue.
CPT-11 is a semisynthetic camptothecin derivative that is approved for the treatment of metastatic colorectal cancer. Currently, several studies are evaluating the efficacy of CPT-11 in the treatment of solid tumors (Conroy et al., 2005; Delord et al., 2005; Reardon et al., 2005; Stathopoulos et al., 2005) . Metabolism of CPT-11 is complex with the involvement of several enzymatic reactions (Rivory, 2000; Slatter et al., 2000) . CYP3A4-dependent oxidation of CPT-11 results in the formation of APC and NPC (Haaz et al., 1998; Sai et al., 2001) ; carboxylesterase-dependent hydrolysis of CPT-11 and NPC results in the formation of the active metabolite SN-38 (Humerickhouse et al., 2000; Khanna et al., 2000; Sanghani et al., 2004) and UGT1A1 glucuronidates SN-38 to form the inactive SN-38-glucuronide (Hanioka et al., 2001 ). The key step in the metabolism of CPT-11 is its activation by carboxylesterases. There are three known human carboxylesterases, CES1, CES2, and CES3. CES2 has 100-and 2000-fold greater catalytic efficiency for irinotecan hydrolysis than CES1 and CES3, respectively . Therefore, CES2, which is predominantly expressed in the liver, small intestines, and colon (Satoh et al., 2002) , is the most important carboxylesterase for the activation of CPT-11. Clinical data, reported by Xu et al. (2002) , indicate that CPT-11 is not effective therapy for lymphomas and gallbladder tumors that do not express CES2. Therefore, understandThis work was supported by a Biomedical Research Grant through the Indiana University School of Medicine and by a grant from the Hoosier Oncology Group. M.A.S is supported by a Translation Research Fellowship through the Indiana University School of Medicine. Mass spectrometric analysis was supported in part by the Indiana Genomics Initiative and by the Indiana 21st Century Research and Technology Fund.
1 CES2 is the normal form that has been extensively studied. CES2⌬
ing the expression of CES2 and its variants is vital for the effective use of CPT-11. A major problem associated with CPT-11 therapy is high interindividual variation both in patient response and in plasma SN-38 levels (Canal et al., 1996; Lokiec et al., 1996; Gupta et al., 1997; Rivory et al., 1997; Couteau et al., 2000) . One possible explanation for this is variable expression of CES2. Our study in 24 colon tumors found a 23-fold variation in CES2 expression (Sanghani et al., 2003) . Hosokawa et al. (1995) have reported high interindividual variation in the specific activities of 12 human liver carboxylesterase samples, ranging from 5 to 45-fold with respect to 10 different substrates. Likewise, a 15-and 3-fold variation in the expression of CES2 has been reported in cytosolic and microsomal fractions of 13 liver samples (Xu et al., 2002) . Large interpatient variability in plasma levels of SN-38 could be indicative of genetic polymorphism. However, pharmacogenomics studies for CES2 have not come to a consensus on the association of SNPs with CES2 expression or activity (Wu et al., 2003; Charasson et al., 2004; Marsh et al., 2004; Kubo et al., 2005) .
Our recent analysis of the full-length expressed sequence tags (ESTs) for CES2 revealed that alternate splicing could give rise to multiple CES2 proteins. The genomic locus of the CES2 gene contains 12 exons (Fig. 1) . The complexity of the CES2 gene arises from the presence of two in-frame ATGs (ATG-1 and ATG-2) in exon 1 (Wu et al., 2003) and alternative splicing in exons 1 and 10. Combination of in-frame ATGs and alternative splicing can give rise to six possible CES2 variant proteins. The two proteins that are the focus of this report are shown in Fig. 1 . The normal CES2 protein is generated from translation starting at ATG-2 (boxed in Fig.  1 ) and has an N-terminal endoplasmic reticulum signal peptide and a C-terminal endoplasmic reticulum retention signal. Alternative splicing in exon 10 (marked by a star in Fig.  1 ) removes the last 48 nucleotides of that exon from the final transcript. The resulting CES2⌬ 458 -473 protein lacks the 16 amino acids directly following the active site histidine. Currently, there is no information regarding the activity, expression, or function of the CES2⌬ 458 -473 variant. In this study, we report the cloning, expression, and irinotecan hydrolase activity of CES2⌬ 458 -473 . We also report the expression of CES2 and CES2⌬ 458 -473 in colon adenocarcinomas with paired normal colon tissue.
Materials and Methods
Colon Tissue. The collection and use of human colon samples were approved by the Institutional Review Board. The tumors were primary colon carcinomas of various grades and stages from all segments of the colon. Corresponding normal colon specimens were paired with each tumor. The specimens originated from surgery samples that were reviewed by a pathologist. All samples were immediately frozen in liquid nitrogen and maintained at Ϫ70°C until use.
RNA Isolation and Reverse Transcription. Tissues, ϳ5 to 30 mg, were disrupted in RLT buffer (QIAGEN, Valencia, CA) using a disposable mortar and pestle (Kontes, Vineland, NJ). Disruption was followed by homogenization via Qiashreddar columns (QIAGEN). Total RNA was isolated using the RNeasy Plus Mini Kit (QIAGEN). Fig. 1 . Complexity of the CES2 gene: the genomic locus of CES2 spans approximately 10 kb and contains 12 exons. Exon 1 contains two in-frame ATGs, ATG-1 and ATG-2. Alternative splicing in exon 1 (dashed line) adds 270 nucleotides to the message putting the first in-frame ATG in exon 2, ATG-3. Alternate 5Ј-splicing in exon 10 (૽) removes 48 nucleotides from the message. Translation initiation at ATG-2 and alternative splicing in exon 10 yields two proteins, normal CES2 and CES2⌬ 458 -473 , which lacks the 16 amino acids immediately following the active site histidine. Both the proteins have an N-terminal signal peptide (f) and a C-terminal ER retention signal ( ). Positions of the catalytic residues serine (S), glutamic acid (E), and histidine (H) and glycosylation sites (GLY) are marked.
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RNA was quantified using a ND-1000 Spectrophotometer (Nanodrop, Wilmington, DE). RNA quality was assessed by running 500 ng of total RNA on a 1% agarose gel. The GeneAmp Gold RNA PCR kit (Applied Biosystems, Foster City, CA) was used for reverse transcription with 1 g of total RNA added to a 50-l reaction. The reaction components were 2.5 mM MgCl 2 , 250 M of each deoxynucleotide triphosphate, 1.25 M oligodeoxythymidylic acid primer, 0.5 U/l RNase inhibitor, and 0.75 U/l MultiScribe reverse transcriptase. Reaction conditions were described previously (Sanghani et al., 2003) .
Real-Time PCR. We modified our real-time PCR protocol from that previously published (Sanghani et al., 2003) to distinguish between the two CES2 variants. Variant-specific forward primers were designed for CES2, 5Ј-CCATGGTGATGAGCTTCCTTTTGT-3Ј, and CES2⌬ 458 -473 , 5Ј-AGGCAGACCATGTTAAATTCACTGA-3Ј. The reverse primer 5Ј-AGGTATTGCTCCTCCTGGTCGAA-3Ј was common to both transcripts. The expected lengths of the PCR products were 186 and 145 bp for CES2 and CES2⌬ 458 -473 , respectively. The PCR conditions were 3 mM Mg 2ϩ , 0.5 M of each primer, and 0.2 mM of deoxynucleotide triphosphates using the SYBR Green kit (Applied Biosystems). The cDNA equivalent to 20 ng of RNA was added to each 25-l PCR reaction. PCR cycling conditions were 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 30 s, 65°C for 30 s, and 72°C for 1 min on an Eppendorf Mastercycler EP instrument (Eppendorf, Westbury, NY). The uniformity of the PCR products was determined using the melt curve function. A standard curve for each gene was generated using clones that were constructed in our laboratory. The copy numbers of each variant present in the tissues were determined by comparison with the appropriate standard curve. All cDNA samples were analyzed in triplicate for each transcript.
Tissue Lysate Preparation. Approximately 10 to 60 mg of colon tissue was homogenized in 100 to 200 l of 25 mM KH 2 PO 4 , pH 7.5, plus 0.05% Triton X-100, leupeptin (10 g/ml), pepstatin (1 g/ml), and DNase (0.5 g/ml) using motorized pestles with microfuge tubes (Kontes). The lysates were centrifuged at 40,000g for 15 to 20 min at 4°C. The supernatant was collected for use in activity assays. Protein content was quantified via the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA) with bovine serum albumin used for a standard curve.
Cloning of the CES2⌬ 458 -473 Variant. A partial EST clone for CES2⌬ 458 -473 was obtained from American Type Culture Collection (Image Clone identification no. 6195662; American Type Culture Collection, Manassas, VA). The EST clone was digested with XbaI and SmaI restriction enzymes, and the 0.65-kb fragment was gel purified (QIAGEN) for ligation. A CES2 clone in the pVL1392 baculovirus transfer vector was subjected to complete digestion with XbaI and partial digestion with SmaI. The digested vector was treated with 1 l of calf intestine phosphatase (NEB, Ipswich, MA) for 1 h at 37°C and then purified using a QIAGEN PCR purification kit. The 0.65-kb CES2⌬ 458 -473 insert was ligated into the vector using T4 DNA ligase (Fastlink; Epicenter, Madison, WI). The clones were analyzed by restriction digest, and two clones with the correct digestion patterns were isolated. Sequencing confirmed the presence of the 48-bp deletion.
Purification of the CES2⌬ 458 -473 Protein Expressed in Insect Cells. The CES2⌬ 458 -473 protein was expressed using the baculovirus system (BD Biosciences PharMingen, San Diego, CA) as reported previously Sun et al., 2004) . The CES2⌬ 458 -473 -pVL1392 vector was cotransfected with linearized Baculogold DNA (BD Biosciences PharMingen) into 2.5 ϫ 10 6 Sf9 cells following the manufacturer's protocol. The CES2⌬ 458 -473 recombinant virus was collected on day 8 post-transfection. The recombinant virus was amplified and used for protein expression. An 800-ml culture of Sf9 insect cells was infected with the CES2⌬ 458 -473 recombinant virus. The cells were collected 70 h postinfection by centrifuging at 500g for 5 min. The cell pellet was sonicated in 30 ml of 20 mM Tris buffer, pH 7.4, containing 1 mM benzamidine, 1 mM dithiothreitol, 1 M leupeptin, and 0.1% Triton X-100. The lysate was ultracentrifuged at 100,000g for 45 min. The recombinant CES2⌬
458 -473 variant was purified by a two-step purification protocol using concanavalin A affinity chromatography and preparative nondenaturing PAGE (Sun et al., 2004) . CES activity and protein concentrations were monitored in the eluted fractions. The protein elution profile for the CES2⌬ 458 -473 variant was compared with that for CES2. A protein peak was detected at the same position as CES2; however, it did not have any activity for the substrate 4-methylumbelliferyl acetate. Fractions from this peak were concentrated and loaded onto an 8.5-cm 6% nondenaturing preparative polyacrylamide gel as described earlier (Sun et al., 2004) . Once again, a protein peak was identified that eluted similarly to CES2. The eluted fractions representing the protein peak were pooled and concentrated.
Characterization of the CES2⌬ 458 -473 Protein. Two micrograms each of purified CES2 and CES2⌬ 458 -473 proteins were separated by SDS-PAGE followed by Western blotting analysis. Antibodies were raised in rabbit to the deglycosylated human CES2 protein.
The antibody was purified from 8 ml of serum using the DEAE Affi-Gel Blue (Bio-Rad) according to the manufacturer's protocol. The purified anti-CES2 antibody was diluted 5000ϫ, and the secondary antibody was horseradish peroxidase-conjugated. SDS-PAGE and Western blotting identified a protein band of approximately 60 kDa. Matrix-assisted laser desorption ionization/time of flight and liquid chromatography/electrospray ionization quadruple time-offlight analysis were used to further confirm the identity of the 60-kDa band.
Circular dichroism spectra for the proteins were determined using a J-720 spectropolarimeter (Jasco, Easton, MD). Both the CES2 and CES2⌬
458 -473 proteins were buffer-exchanged and equilibrated in 5 mM potassium phosphate, pH 7.5, containing 10% ethylene glycol. A final concentration of 0.22 mg/ml of each protein was used for analysis. Each spectrum was an average of three scans using a 0.1-cm quartz cell. Spectra were recorded in the 250 to 190-nm range at a speed of 100 nm/min and with a resolution of 0.2 nm. The mean residue molar ellipticity [] MRW was calculated using eq. 1:
where is in millidegree, n is the number of amino acid residues in the protein, C p is the molar concentration of the protein (in moles per liter), and l is the cuvette path length in centimeters. For secondary structure analysis, the ellipticity was expressed as ⌬ MRW in molar per centimeter units using eq. 2. The spectra were then analyzed using the CDPro software developed by Woody (1993, 2004 ). An extended protein basis set of 43 soluble and 13 membrane proteins was used for analysis. Of the three methods for calculating the secondary structure composition of the protein in the CDPro software, CONTIN/LL produced the most reliable results (Provencher and Glockner, 1981) . Carboxylesterase Activity Assays. The hydrolysis of 4-methylumbelliferyl acetate was monitored by a spectrophotometric assay described earlier Sanghani et al., 2003) . CES2 band density was determined by analyzing the samples on a nondenaturing PAGE and staining for carboxylesterase activity using 4-MUA as described earlier (Dean et al., 1995; Sanghani et al., 2003) .
CPT-11 Hydrolysis Assay. The CPT-11 hydrolase activities of the purified CES2 and CES2⌬ 458 -473 proteins were evaluated as reported earlier . In 250-l reactions, 55 M CPT-11 was incubated with varying concentrations of CES2 (0 -30 g) and CES2⌬
458 -473 (0 -50 g) in HEPES buffer, pH 7, at 37°C for 30 min and 2 h, respectively. The reaction was stopped by the addition of 670 l of 0.1 M HCl. Fifteen microliters of 0.14 mM camptothecin was added as internal standard. Samples were extracted using solid-phase columns (Oasis HLB column; Waters, Mil- ford, MA), processed, and analyzed as described earlier . The standard curve samples, 0 to 5 M SN-38, were processed in a similar fashion. The ratios of area under the curve for SN-38 and camptothecin were plotted against concentration (GraphPad Prism 4.0, San Diego, CA) and the unknown concentrations were calculated from the standard curve.
Statistical Analysis. Skewness, kurtosis, and overall normality of copy number, 4-MUA hydrolase activity, and band density data were assessed using the methods of D' Agostino et al. (1990) . The copy numbers for CES2 were independently subjected to linear regression analysis against both 4-MUA hydrolase activity and band density using JMP 4.0 (SAS Institute Inc., Cary, NC). The data are considered significant if p Ͻ 0.05.
Results
CES2 is a serine ester hydrolase (carboxylesterase) with Ser228, Glu345, and His457 forming its catalytic triad. CES2 is the major carboxylesterase responsible for activation of CPT-11 (Humerickhouse et al., 2000; Khanna et al., 2000; Sanghani et al., 2004) . A variant DNA sequence for CES2 was reported in the EST database. This variant transcript has a 48-bp deletion ( Fig. 2A) that gives rise to a protein with a 16-amino acid deletion immediately following the active site His457 residue (Fig. 2B) . Use of the SPIDEY software (http://www.ncbi.nlm.nih.gov/IEB/Research/Ostell/Spidey/ index.html) to align the CES2 (GI:37622884) and CES2⌬ 458 -473 (GI:37622886) mRNA transcripts with the CES2 genomic clone (GI:56788327) demonstrates that the exon 10 sequence contains good 5Ј splice sites for both of the transcripts. Hence, the two transcripts are created by the use of alternate 5Ј donor splice sites in exon 10. This evidence is further supported by the identification of 14 EST sequences in the human EST database as determined by blasting the database with a 25-nucleotide sequence unique to CES2⌬ 458 -473 (shown in bold in Fig. 2A) .
Analysis of CES2 and CES2⌬ 458 -473 Expression in Human Colon Samples. Real-time PCR was used to quantify the expression levels of the CES2 and CES2⌬ 458 -473 transcripts in 10 paired tumor and normal colon samples. Forward primers (shown in bold in Fig. 2A ) were designed to be variant-specific for CES2 and CES2⌬ 458 -473 . Analysis of RNA quality by agarose gel electrophoresis showed little to no degradation. Standard curves were created for each variant using DNA clones constructed in our lab. Amplification of each standard curve was linear over a 100,000-fold range (r 2 ϭ 0.99) with respect to copy numbers. The amplification efficiency for each of the variants was Ն0.9. All cDNA samples were analyzed in triplicate with the S.D., generally Ͻ12% for both CES2 and CES2⌬ 458 -473 . The repeatability of all the steps involved in real-time PCR was studied in control experiments. In one experiment, RNA was isolated from five different pieces of the same tumor sample. It was determined that Ͻ1.6-fold variation in the CES2 copy numbers could be attributed to the entire method from tissue disruption through real-time PCR. In another experiment, one sample RNA was reverse transcribed in quintuplicate. It was determined that Ͻ1.3-fold variation in copy number could be attributed to reverse transcription.
CES2 and CES2⌬ 458 -473 were found in all of the tumor and normal colon samples. There was a 45-fold variation in expression of CES2 transcript in normal tissue and a 27-fold variation in tumor tissue. Four patients expressed more CES2 in tumor as compared with normal tissue (Fig. 3A) 458 -473 . A, real-time PCR was used to determine the amount of CES2 transcripts in 10 paired tumor and normal colon samples. A 45-fold variation in expression of CES2 was found among the normal samples, and a 27-fold variation was found for the tumor samples. There was no disease-specific expression pattern. B, CES2⌬ 458 -473 was expressed in all of the colon tissues samples. CES2⌬ 458 -473 accounts for ϳ6% of total CES2 transcript in all of the colon samples.
CES2 Splice Variant 97
at ASPET Journals on January 29, 2018 jpet.aspetjournals.org Downloaded from imately 6% (S.D. Ͻ 1.3%) of the total CES2 transcripts (Fig.  3B) .
Carboxylesterase Activity in Colon Tissue Lysates. The carboxylesterase activities of the colon tissue lysates were quantified using the 4-methylumbelliferyl acetate hydrolysis assay and band densitometry analysis as described under Materials and Methods. All samples showed nonspecific carboxylesterase activity with 4-MUA as substrate (Table 1). The range for normal samples was 2.5 to 9.8 mol mg Ϫ1 h Ϫ1 with a 4-fold variation, whereas the range for the tumor samples was 2.0 to 7.4 mol mg Ϫ1 h Ϫ1 with a 3.7-fold variation. Nondenaturing PAGE was used to separate the carboxylesterases in the samples, and purified CES2 protein was loaded on each gel as a control. The band density attributable to CES2 was determined for each sample. All samples demonstrated activity for 4-MUA in the nondenaturing PAGE assay (Table 1 ). There was a 23-fold variation in normalized band density among the normal colon samples and an 8-fold variation among the tumor samples.
Statistical Analysis. There was evidence of kurtosis (data not shown) for both the CES2 copy numbers (p ϭ 0.03) and band densities (p ϭ 0.04) of the tumor samples. Kurtosis is often an indication of bimodality (Darlington, 2007) . All other measurements in tumor and all measurements in normal tissue appeared to be normally distributed. CES2 copy numbers, determined by real-time PCR, were subjected to linear regression analysis (JMP 4.0) with 4-MUA hydrolase activity and normalized band density (Fig. 4) . Correlations of CES2 expression with 4-MUA hydrolase activity and band density are considered significant if p Յ 0.05 (Takahashi et al., 2000) . CES2 copy numbers, in tumor samples, positively and significantly (p Յ 0.0001) correlated with both 4-MUA hydrolase activity (r 2 ϭ 0.857) and band density (r 2 ϭ 0.982). For the normal samples, CES2 copy numbers significantly correlated with 4-MUA hydrolase activity (p Ͻ 0.0436), but correlation with band density (p Ͻ 0.0546) was just outside the range of significance. Data from the normal and tumor samples were analyzed collectively, and significant correlation existed between CES2 copy numbers and both 4-MUA (p Ͻ 0.0001) and band density (p Ͻ 0.001).
Expression and Purification of the CES2⌬
-473
Protein Variant. The CES2⌬ 458 -473 variant was expressed in Sf9 insect cells using a recombinant baculovirus containing the CES2⌬ 458 -473 cDNA. The recombinant CES2⌬ 458 -473 virus was confirmed by PCR. A two-step purification protocol comprised of concanavalin A chromatography and preparative nondenaturing gel electrophoresis was used to purify CES2⌬ 458 -473 to near homogeneity. Due to its lack of 4-MUA hydrolase activity, during each purification step, the protein elution profile of CES2⌬ 458 -473 was compared with CES2 to identify the protein peak of interest. The protein elution profile for CES2⌬ 458 -473 was similar to CES2 for both purification steps.
TABLE 1 Expression and activity data for paired tumor (T) and normal (N) colon tissue samples
Ten microliters of colon tissue lysate was incubated with 0.5 mM 4-MUA in 90 mM potassium phosphate containing 40 mM potassium chloride buffer, pH 7.4, at 37°C. Specific activity for 4-MUA was calculated in micromoles per milligram per hour. CES2 band density was determined by running 50 to 100 g of colon tissues lysates on nondenaturing PAGE. The gels were exposed to 1 mM 4-MUA in 100 mM potassium phosphate buffer, pH 6.0, for 10 min at room temperature. Band density was measured by fluorescence. Band densities were normalized to CES2 controls to account for variations between gels. jpet.aspetjournals.org
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Characterization of the CES2⌬ 458 -473 Protein. The purified CES2 and CES2⌬ 458 -473 proteins were analyzed by SDS-PAGE (Fig. 5A) , Western blot analysis (Fig. 5B) , nondenaturing polyacrylamide gel electrophoresis (Fig. 5, C and D), circular dichroism (Fig. 5E) , and mass spectroscopy to assess their identity, purity, and physical properties. The calculated molecular mass of CES2⌬ 458 -473 protein from the SDS-PAGE gel (Fig. 5A ) is 59 kDa, and the expected molecular mass is 57.3 kDa before glycosylation. In the Western blot analysis, both CES2 and CES2⌬ 458 -473 were identified with an anti-CES2 antibody (Fig. 5B) . Activity staining of the nondenaturing polyacrylamide gel showed that the CES2⌬ 458 -473 protein lacks carboxylesterase activity for 4-MUA (Fig. 5C ). Coomassie Blue stain of the same gel shows the protein in the CES2⌬
458 -473 lane (lane 2, Fig. 5D ) migrating to the same place as CES2 (lane 1, Fig. 5D ). The identity of the recombinant CES2⌬ 458 -473 protein was confirmed by mass spectroscopy, where a tryptic peptide with one miscleavage, ADHVKFTEEEEQLSR, specific for CES2⌬ 458 -473 (underlined in Fig. 2B ) was identified. Folding of CES2⌬ 458 -473 protein was evaluated by circular dichroism. The mean residue molar ellipticity was plotted as a function of wavelength (Fig. 5E ). The secondary structure composition analysis was done with CDpro software. Results from the CONTIN/LL method showed that the compositions of CES2 and CES2⌬ 458 -473 were 15% ␣-helical, 34% ␤-strand, 22% turn, and 29% unordered and 20% ␣-helix, 29% ␤-strand, 22% turn, and 29% unordered, respectively.
CPT-11 Hydrolase Assay. CES2⌬ 458 -473 protein (0 -50 g) was incubated with 55 M CPT-11 for 2 h to determine its CPT-11 hydrolase activity. Under these conditions, no significant SN-38 (Ͻ 5 nM) peak was detected in any of the CES2⌬ 458 -473 samples after 2 h. In comparison, 1.98 M SN-38 was detected when CES2 (30 g) was incubated with the same concentration of CPT-11 for just 30 min (Fig. 6) .
Discussion
Irinotecan is a commonly used therapeutic for colorectal cancer, but there is high interindividual variation in response to this treatment. Carboxylesterases in the liver convert the prodrug CPT-11 to its active form SN-38, which is 1000ϫ more cytotoxic. CES2, located predominately in the liver and intestine, is the most important enzyme for this activation (Humerickhouse et al., 2000; Sanghani et al., 2004) . Irinotecan has shown to be ineffective therapy for lymphomas and gallbladder tumors that lack CES2 expression, suggesting that local expression of CES2 in tumors may influence treatment outcome (Xu et al., 2002) . CES2 SNPs have been identified, but there is no consensus as to the effect of the SNPs on expression and activity (Wu et al., 2003; Charasson et al., 2004; Marsh et al., 2004; Kubo et al., 2005) . Analysis of CES2 transcripts in the EST database reveals that combinations of alternate ATG start sites and two splicing events could lead to six potential proteins. A 25-nucleotide sequence (shown in bold in Fig. 2A ) unique to the CES2⌬ 458 -473 transcript was identified in 14 ESTs. The transcript is missing the final 48 nucleotides from exon 10, and the resulting protein CES2⌬ 458 -473 lacks the 16 amino acid residues directly following the active site histidine. The proximity of the deleted amino acids to the active site suggested that CES2⌬
458 -473 may differ in activity from CES2. The expression levels of the CES2⌬ 458 -473 and CES2 transcripts were analyzed in tumor and normal colon tissue pairs using variant specific primers and real-time PCR. Primers were able to distinguish between alternate splicing events in exon 10 but could not detect any splicing events occurring in exon 1. Thus, copy numbers for CES2⌬ 458 -473 and CES2 represented the total transcript levels differentiating only between normal and alternate splicing in exon 10, with no regard for alternative splicing in exon 1. Both the CES2⌬ 458 -473 and CES2 variants were present in all 20 tissue samples, and CES2⌬ 458 -473 accounted for approximately 6% of the total CES2 transcript, suggesting that it was being spliced at a constant rate. There was large interindividual variation in CES2 expression among the tumor tissue samples and the normal colon samples, 27-and 45-fold, respectively. There was no significant difference in CES2 expression between 458 -473 and CES2 proteins. Lane 1, 2 g of CES2; lane 2, 2 g of CES2⌬ 458 -473 . A, SDS-PAGE stained with Coomassie Blue. B, Western blot of the same gel using CES2 antibody. C, nondenaturing PAGE stained for activity with 4-MUA. D, nondenaturing PAGE from C stained for protein with Coomassie Blue. E, circular dichroism spectrum of CES2 (E2) and CES2⌬ 458 -473 (V2) performed under identical conditions. 458 -473 proteins were incubated with 55 M CPT-11. The reactions were carried out in 250-l volume at 37°C. CES2 samples were incubated for 30 min and CES2⌬ 458 -473 samples for 2 h. SN-38 formation was quantified by high-performance liquid chromatography as described under Materials and Methods. SN-38 concentration was plotted as a function of protein concentration.
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tumor and normal colon samples, which supports the findings of our previous report (Sanghani et al., 2003) . In six paired samples, CES2 expression was greater in the normal tissues, whereas the other four pairs have higher expression in tumor. This variability suggests that interindividual variation in expression of CES2 could account for differences in patient response to irinotecan therapy. CES2 expression levels, especially in tumor tissue, may dictate whether or not irinotecan therapy is successful, whereas CES2 expression levels in normal tissue may contribute to the severity of deleterious side effects.
CES2 expression levels were subjected to linear regression analysis with two different measures of carboxylesterase activity, 4-MUA hydrolysis and band density. Unlike our previous study (Sanghani et al., 2003) , variant-specific primers were used to quantify the transcript for CES2 separately from the transcript for CES2⌬ 458 -473 . CES2 expression in the colon tumor samples had significant positive correlation with 4-MUA hydrolase activity and band density. These findings are in concordance with the data previously published by Sanghani et al. (2003) , although the correlation coefficients are increased. These increased correlations may be attributable to the use of variant specific primers as well as improved methods. CES2 expression in normal tissue was also found to have significant, positive correlation with 4-MUA hydrolase activity and positive correlation with band density (p Յ 0.055). Correlation values between expression and activity for the tumor samples were greater than the corresponding correlation values in normal samples. It is possible that the tumor samples are more homogenous in cell type than the normal samples, which may include muscular tissue in addition to mucosal tissue.
If interindividual variation in response to CPT-11 treatment may be explained by variations in CES2 expression, it is important to examine the properties of the CES2⌬ 458 -473 variant. CES2⌬ 458 -473 was cloned and expressed to characterize its activity and physical properties. When purifying the CES2⌬ 458 -473 variant protein, the protein elution profile of CES2 was used as a guide. The CES2⌬ 458 -473 protein had an elution profile identical to CES2 for purification on concanavalin A and preparative nondenaturing PAGE. Binding of the CES2⌬ 458 -473 protein to concanavalin A resin indicates that it is glycosylated. CES2 and CES2⌬ 458 -473 proteins migrated similarly on nondenaturing PAGE (Fig. 5D ). When incubated with 4-MUA, a substrate for which CES2 has high activity with a reported K cat /K m value of 60,000 mM Ϫ1 min Ϫ1 (Pindel et al., 1997) , CES2⌬ 458 -473 demonstrated no activity.
The lack of esterase activity demonstrated by the CES2⌬ 458 -473 protein raised questions regarding its folding. The circular dichroism spectrum for CES2⌬ 458 -473 (Fig. 5E ) shows the presence of a secondary structure similar to that of CES2. The small increase in ␣-helical content and small decrease in ␤-strand content of CES2⌬ 458 -473 in comparison with CES2 could be expected from the 16-amino acid deletion. The identities of the recombinant proteins were further confirmed by mass spectroscopy. Although the CES2⌬ 458 -473 protein lacked 4-MUA hydrolase activity, it was feasible that it retained activity for other substrates. The CPT-11 hydrolase activity of the CES2⌬ 458 -473 protein was evaluated. Even at the highest concentration of CES2⌬ 458 -473 protein, no significant amount of SN-38 (Ͻ5 nM) was detected. Based on these results, we concluded that the CES2⌬ 458 -473 protein lacked irinotecan hydrolase activity.
Alternative splicing is emerging as a major mechanism for proteome diversity and differential splicing occurs in disease specific manner, especially in cancer (Garcia-Blanco et al., 2004; Venables, 2004 Venables, , 2006 . The role of CES2 splice variants in ester drug metabolism has not been evaluated. We show that the CES2⌬ 458 -473 variant is expressed at a low and constant level of 6% of total CES2. The low expression and lack of activity of CES2⌬ 458 -473 suggest that it is not a determinant for CPT-11 pharmacokinetics and therapeutic outcome. However, if any of the remaining variants are found to have significant expression levels or activities that differ from CES2, it may further the understanding of the interindividual variation in ester drug metabolism.
